TickerKhojTrading & Distribution · Wholesale Distributors · NSE: SAROJA · data 2026-11-02
Saroja Pharma Industries India Ltd.
In plain words
Price: 10.4% below its 52-week high of ₹43.3.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹71 cr |
| Net profit (last 12 months) | ₹2 cr |
| Sales growth, 3 years (yearly) | 11.8% |
| Profit growth, 3 years (yearly) | 15.0% |
At a glance
P/E 9.7, P/B 0.9, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 9.8%, ROCE 17.9%, operating margin 5.7%: how much profit it earns on the money it uses.
Debt/equity 0.83, Profit growth 15.0% and sales growth 11.8% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 15.0% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions
- Delivery vs usual 0/30: No stored daily delivery history for this stock (0 points).
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Common questions
Is Saroja Pharma Industries India Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.83.
What is Saroja Pharma Industries India Ltd.'s P/E ratio?
About 9.7, based on the last 12 months' earnings and a price of ₹38.8 (data 2026-11-02).
What is the 52-week high and low of Saroja Pharma Industries India Ltd.?
The 52-week high is ₹43.3 and the 52-week low is ₹28.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Saroja Pharma Industries India Ltd. | ₹38.8 | ₹16 cr | 9.7 | 0.9 | 9.8% | 17.9% | 0.83 | -11.1% |
| QVC Exports Limited | ₹24.15 | ₹25 cr | 7.6 | — | 4.9% | 7.9% | 1.06 | -24.5% |
| Aspire & Innovative Advertising Limited | ₹16.2 | ₹23 cr | 9.7 | — | 5% | 2.6% | 0.34 | -12.4% |
| Sri Havisha Hospitality And Infrastructure Ltd | ₹1.24 | ₹19 cr | — | — | -21.9% | -3.5% | 2.37 | -37.7% |
| Agarwal Float Glass India Limited | ₹25.5 | ₹18 cr | 12.6 | 0.9 | 7.6% | 18.2% | 0.82 | -54.8% |
| Shrenik Limited | ₹0.25 | ₹15 cr | — | — | — | — | — | -57.6% |
Compare SAROJA with QVCEL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open SAROJA in TickerKhoj →